This study proposes to conduct a prospective, multicenter, single-arm study to explore the efficacy and safety of venetoclax in combination with high-dose decitabine (DEC3-VEN) in new diagnosed adult patients with AML, and to provide evidence for the optimal selection of clinical treatment regimens, which is planned to be conducted in 10 research centers across the country.

开始日期2024-03-01

申办/合作机构

泰安市中心医院

[+5]

ChiCTR2300078636

/ RecruitingN/AIIT

A prospective cohort study of laparoscopic mediastinal lymph node dissection through esophageal hiatus and thoracic pathways for Siewert type II esophageal gastric junction adenocarcinoma

开始日期2024-01-01

申办/合作机构

邯郸市中心医院

100 项与邯郸市中心医院相关的临床结果

登录后查看更多信息

0 项与邯郸市中心医院相关的专利（医药）

登录后查看更多信息

1,047

项与邯郸市中心医院相关的文献（医药）

2025-05-01·European Journal of Radiology

Intracranial vessel wall enhancement scoring system for monitoring disease activity and neuropsychiatric impairment in systemic lupus erythematosus

Article

作者: Geng, Zuojun ; Zhang, Yue ; Zhang, Chengye ; Wang, Yali ; Sun, Yue ; Gao, Duo ; Yang, Haiqing ; Zhou, Lixia ; Li, Zhijuan ; Xiang, Shifeng ; Wang, Sicong ; Zhao, Xueying ; Zhang, Cong

OBJECTIVESTo establish an intracranial vessel wall enhancement (VWE) scoring system and evaluate its potential as a protocol for monitoring systemic lupus erythematosus (SLE) disease activity and neuropsychiatric impairment.MATERIALS AND METHODSIn this retrospective study, fifty patients with SLE underwent conventional MRI and high-resolution magnetic resonance vascular wall imaging (HR-VWI) at three tertiary hospitals between August 2022 and December 2023. We analyzed VWE distribution in intracranial arteries, developed a scoring system based on enhancement patterns, and examined the relationship between VWE scores, disease activity, and cognitive function. Univariate analysis and logistic regression were utilized to identify clinical and imaging characteristics associated with sustained lupus low disease activity state (LLDAS) and central nervous system (CNS) neuropsychiatric impairment.RESULTSSLE patients exhibited multi-segmental intracranial vessel wall thickening with concentric or double-track enhancement. VWE scores positively correlated with disease activity and negatively with cognitive function (both P < 0.001). High VWE scores was negative predictors for achieving sustained LLDAS (OR, 1.52; 95 % CI: 1.01-2.28; P = 0.043). Logistic regression confirmed VWE scores as independent predictors of CNS neuropsychiatric impairment (OR, 1.92; 95 % CI: 1.03-3.60; P = 0.04). A VWE score > 4.0 demonstrated high sensitivity (96 %) and moderate specificity (65 %) for diagnosing CNS impairment (AUC = 0.82; P < 0.001).CONCLUSIONThe VWE scores system can serve as a valuable protocol for monitoring disease activity and detecting CNS neuropsychiatric impairment in SLE, offering a potential tool for early diagnosis and prognosis evaluation.

2025-04-22·The Journal of Clinical Endocrinology & Metabolism

Alteration of Bone Microarchitecture in Hereditary Distal RTA Patients With SLC4A1 Gene Mutation: Assessed by HR-pQCT

Article

作者: Jiang, Yan ; Zhang, Shujie ; Cui, Lijia ; Xia, Weibo ; Xing, Xiaoping ; Chen, Rong ; Du, Juan ; Wang, Ou ; Li, Mei

AbstractContextHereditary distal renal tubular acidosis caused by SLC4A1 gene mutation (SLC4A1-dRTA) is a rare hereditary form of renal tubular acidosis. Rickets or osteomalacia is a common complication of SLC4A1-dRTA and seriously affects patients’ daily lives. However, studies on the bone microstructure in SLC4A1-dRTA are limited.ObjectiveThis work aimed to evaluate the bone microstructure of SLC4A1-dRTA patients, compared to age- and sex-matched healthy controls and X-linked hypophosphatemic rickets (XLH) patients.MethodsThis was a retrospective study of 11 SLC4A1-dRTA patients. Clinical manifestations and biochemical and radiographical examinations were characterized. Bone microstructure was examined in 7 SLC4A1-dRTA patients, 7 healthy controls, and 21 XLH patients using high-resolution peripheral quantitative computed tomography.ResultsSkeletal symptoms, including fracture, bone pain, and lower limb deformity, were present in 72.7% of SLC4A1-dRTA patients. Short stature was present in 63.6% of the patients. SLC4A1-dRTA patients had significantly lower volumetric bone mineral density in the distal tibia and more severe deteriorated trabecular bone in the distal radius and tibia than healthy controls. SLC4A1-dRTA patients had significantly more severely deteriorated trabecular bone in the distal radius and distal tibia compared to XLH patients. With long-term alkaline therapy, SLC4A1-dRTA patients had alleviated bone pain and increased height.ConclusionSkeletal lesions were common clinical manifestations in SLC4A1-dRTA patients. Compared with XLH, another common type of rickets, SLC4A1-dRTA patients had more severe trabecular bone microstructure damage, further supporting the necessity of early diagnosis and timely treatment of the disease.

2025-04-21·Cancer Research

Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study

作者: Liu, Ying ; Liu, Jie ; Lin, Sheng ; Liu, Yi ; Xu, Ling ; Li, Lu ; Zheng, Lu ; Mu, Zhuqing ; Zhou, Jin ; Qi, Yunxiang ; Cheng, Ying ; Liao, Qin ; Shang, Yanhong ; Bi, Jianqiang ; Chen, Xuesong ; Chen, Meifang ; chen, Yongxing ; Xu, Shufeng ; Meng, Zhaoting ; Chen, Jianxin ; Liu, Yu ; Jiang, Yujie ; Ji, Yinghua

AbstractBackground:Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive disease characterized by rapid progression and development of extensive metastases. Standard chemotherapy-based regimens for ES-SCLC often lead to myelosuppression, compromising medication compliance and prognosis. Trilaciclib is a CDK4/6 inhibitor, approved by NMPA in 2022 to decrease the incidence of chemotherapy-induced myelosuppression (CIM) in adult with ES-SCLC. This study aims to evaluate the efficacy and safety of preventive use of trilaciclib prior chemotherapy in Chinese ES-SCLC population under real-world settings.Methods:ES-SCLC patients suitable for combined treatment of trilaciclib and chemotherapy were enrolled in this study. Eligible participant received 240 mg/m2 of trilaciclib IV 4 h prior chemotherapy. The primary endpoint was the incidence rate of severe neutropenia (SN). The secondary endpoints included the occurrence of grade 3/4 hematologic adverse events (HAEs), administration rate of G-CSF and ESA, safety, and anti-tumor efficacy of chemotherapy.Results:A total of 201 ES-SCLC patients receiving at least one dose of trilaciclib combined with chemotherapy were included from 60 centers in China during March 10 2023 to August 10 2024, with median age of 65 (58, 71). Metastases occurred in 90.0% of the subjects at baseline, in which brain metastases accounted for 16%. 92.5% of the patients adopted platinum plus etoposide (E/P) regimen. The mean number of completed chemo-cycle was 3.0 (1.4). In Cycle 1, 1 case (0.6%) of SN occurred in patient receiving second-line (2L) treatment with E/P therapy. Grade 3/4 HAEs were reported in 5.4% of the patients in Cycle 1, including neutropenia (3.6%), anemia (1.2%) and thrombocytopenia (1.8%). During the whole treating period, a total of 5 cases (2.6%) of SN occurred, 4 of which received 2L treatment with E/P, while the remaining one received first-line cis-platinum therapy. 17.5% participants experienced grade 3/4 HAEs during the study, in which neutropenia, anemia and thrombocytopenia accounted for 8.2%, 9.3% and 3.1%, respectively. G-CSF and ESA were used in 2.6% and 1.0% of the patients. As for safety, grade ≥3 AEs were reported in 20.9% of the participants. No AEs-related treatment discontinuation happened. No serious AEs and death occurred. Among 48 patients included into tumor response analysis, the best response to chemotherapy was CR (8.3%), PR (43.8%), SD (39.6%) and PD (8.3%). The objective response rate (ORR) and disease control rate (DCR) reached 52.1% and 91.7%, respectively.Conclusions:Prophylactic administration of trilaciclib (240 mg/m2) prior chemotherapy exhibits superior myeloprotective effect and were well-tolerated in Chinese ES-SCLC population, providing evidence for clinical benefit of trilaciclib as a myelo-protectant.Citation Format:Ying Liu, Jianqiang Bi, Jianxin Chen, Meifang Chen, Xuesong Chen, Yongxing chen, Yinghua Ji, Yujie Jiang, Lu Li, Qin Liao, Sheng Lin, Jie Liu, Yi Liu, Yu Liu, Zhaoting Meng, Zhuqing Mu, Yunxiang Qi, Yanhong Shang, Ling Xu, Shufeng Xu, Lu Zheng, Jin Zhou, Ying Cheng. Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7218.

项与邯郸市中心医院相关的新闻（医药）

2025-02-12

·医药地理

【凤采鸾章·博文集】粒细胞集落刺激因子联合低分子肝素对反复种植失败患者的疗效分析

粒细胞集落刺激因子联合低分子肝素对反复种植失败患者的疗效分析 Efficacy analysis of granulocyte colony-stimulating factor combined with low molecular weight heparin in patients with repeated implantation failure 乔天琪1,2，崔艺舰3，罗怡宁4，高艳霞5，赵海君1，卢静1* (1. 邯郸市中心医院生殖医学科，河北邯郸 056000；2. 河北北方学院研究生学院，河北张家口 075000；3. 邯郸市中心医院输血科，河北邯郸 056000；4. 重庆医科大学公共卫生学院，重庆 401331；5. 邯郸市妇幼保健院检验科，河北邯郸 056000) 引用乔天琪, 崔艺舰, 罗怡宁, 等. 粒细胞集落刺激因子联合低分子肝素对反复种植失败患者的疗效分析[J]. 世界临床药物, 2024, 45(12): 1292-1299. DOI :10.13683/j.wph.2024.12.013. 作者简介乔天琪，主治医师，研究方向：女性生殖内分泌与辅助生殖技术。通信作者：卢静，主任医师，研究方向：女性生殖内分泌与辅助生殖技术。基金项目：河北省科学技术厅健康医疗与生物医药专项(182777197)；河北省邯郸市科学技术研究与发展计划项目(19422083009-7) 摘要目的探讨粒细胞集落刺激因子(granulocyte colony-stimulating factor，G-CSF) 联合低分子肝素(low molecular weight heparin，LMWH) 皮下注射对体外受精/ 卵胞质内单精子注射(in vitro fertilization/intracytoplasmic sperm injection，IVF/ICSI) 周期不明原因反复种植失败(unexplained repeated implantation failure，URIF) 患者冻融胚胎移植(frozen-thawed embryo transfer，FET) 临床妊娠结局的影响。方法分析2017 年1 月至2023 年3 月在邯郸市中心医院生殖医学科行IVF/ICSI 的URIF 患者资料，根据治疗方式分组，FET 周期接受G-CSF 联合LMWH 皮下注射者设为A 组，接受G-CSF 皮下注射者设为B 组；接受LMWH 皮下注射者设为C 组；仅接受常规黄体支持治疗者设为D 组。据患者基本资料行倾向性评分匹配，设定卡钳值0.02。比较本次FET 周期特征、临床妊娠结局、产科结局、新生儿结局及重大不良反应情况。结果本次FET 周期各组患者特征差异均无统计学意义(P ＞ 0.05) ；各组胚胎种植率、临床妊娠率以及β- 人绒毛膜促性腺激素(human chorionic gonadotropin，HCG) 阳性率差异有统计学意义(P ＝ 0.002，P ＝ 0.006，P ＝ 0.007)。各组足月产率、早产率、双胎率、产科并发症率( 妊高症率、胎膜早破率) 以及新生儿并发症率( 巨大儿率、低体质量儿率) 比较，差异均无统计学意义(P ＞ 0.05)。结论 G-CSF 联合LMWH 皮下注射可提高URIF 患者FET 周期的胚胎种植率、临床妊娠率以及β-HCG 阳性率，是URIF 的一种有效治疗手段。关键词粒细胞集落刺激因子；低分子肝素；不明原因反复种植失败；胚胎种植率；临床妊娠率章节导览 1 资料与方法 1.1 研究对象 1.2 纳排标准 1.3 分组及方法 1.3.1 冻融胚胎移植方案 1.3.2 方法 1.4 观察指标 1.4.1 主要观察指标 1.4.2 次要观察指标 1.5 药物不良反应情况 1.6 统计学方法 2 结果 2.1 一般资料 2.2 FET 周期特征 2.3 临床妊娠结局比较 2.4 产科情况及新生儿结局 2.5 不良反应情况 3 讨论 4 结论文章节选我国约18% 的育龄夫妇不孕不育。另有研究显示，约10% 体外受精- 胚胎移植(in vitro fertilization-embryo transfer，IVF-ET) 患者多次移植后未成功妊娠。反复种植失败(repeated implantation failure，RIF) 可能与母体、胚胎等因素有关，经全面筛查后仍原因不明的RIF 称为不明原因RIF(unexplained repeated implantation failure，URIF)。本研究分析粒细胞集落刺激因子(granulocyte colony-stimulating factor，G-CSF) 联合低分子肝素(low molecular weight heparin，LMWH)皮下注射治疗URIF 患者的临床效果，以期为临床提供参考。 ↑长按二维码阅读原文聚焦药物综合评价促进临床合理用药请看《世界临床药物》！本刊为月刊，大16开。邮发代号4-302，全国各地邮局均可订阅。定价：26元，全年312元。订阅电话：021-62790477-751 订阅传真：021-62473200 订阅邮箱：guohx@pharmadl.com END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

临床研究申请上市临床结果

100 项与邯郸市中心医院相关的药物交易

登录后查看更多信息

100 项与邯郸市中心医院相关的转化医学

登录后查看更多信息